Table 5 Univariate analysis of the predictors for the 30-day mortality

 Age, year

63.0 (18.5)

61.8 (16.5)

0.644

 Female gender

9 (39.1%)

16 (29.6%)

1.53 (0.55–4.24)

0.415

 Hepatic dysfunction

0 (0.0%)

2 (3.7%)

0.69 (0.60–0.81)

1.000

 Renal insufficiency

1 (4.3%)

6 (11.1%)

0.36 (0.41–3.21)

0.667

 Chronic pulmonary disease

6 (26.1%)

15 (27.8%)

0.92 (0.30–2.78)

0.879

 Heart disease

2 (8.7%)

11 (20.4%)

0.37 (0.08–1.83)

0.323

 Diabetes mellitus

2 (8.7%)

2 (3.7%)

2.48 (0.33–18.75)

0.578

 Immune compromise

2 (8.7%)

3 (5.6%)

1.62 (0.25–10.40)

0.632

 Malignancy

2 (8.7%)

5 (9.3%)

0.93 (0.17–5.20)

1.000

 Hypoproteinemia

0 (0.0%)

2 (3.7%)

0.69 (0.60–0.81)

1.000

 Surgery

5 (21.7%)

11 (20.4%)

1.09 (0.33–3.58)

1.000

 CURB65 score, mean ± SD

2.7 (1.1)

1.7 (0.8)

0.001

 Mechanical ventilation

21 (91.3%)

27 (50.0%)

10.5 (2.24–49.24)

0.001

 Albumin

32.2 (4.9)

32.1 (4.3)

0.916

 Bacteremia

5 (21.7%)

2 (3.7%)

7.22 (1.29–40.54)

0.022

 Tigecycline resistance

16 (69.6%)

19 (35.2%)

0.24 (0.08–0.68)

0.006

 Airway eradication of MDRAB

5 (27.8%)

19 (48.7%)

0.40 (0.12–1.35)

0.137

Duration, days

10.0 (6.6)

12.4 (5.8)

0.014

 With sulbactam

19 (82.6%)

45 (83.3%)

0.95 (0.26–3.47)

1.000

 With carbapenems

1 (4.3%)

3 (5.6%)

0.77 (0.08–7.84)

1.000

 With amikacin

1 (4.3%)

2 (3.8%)

1.16 (0.10–13.46)

1.000

 With fluoroquinolones

1 (4.3%)

3 (5.6%)

0.77 (0.08–7.84)

1.000

 Delayed tigecycline treatment

6 (26.1%)

15 (27.8%)

0.92 (0.30–2.77)

0.879